Core Viewpoint - The company is focused on customer demand, optimizing its marketing system, and enhancing market layout to drive steady performance growth in the first half of 2025 [1] Group 1: Marketing Strategy - The company has developed a broad marketing network with multiple sales channels to improve market coverage [1] - A multi-brand sales strategy is being continuously optimized to enhance market penetration [1] Group 2: Team Development - The company is expanding its marketing team by attracting high-end marketing talent and optimizing the compensation system to boost the initiative and enthusiasm of the sales team [1] Group 3: Market Strategy - The company conducts precise assessments of downstream market trends and timely expands production capacity to seize market opportunities [1] - A series of optimization measures in the marketing system have effectively driven the company's steady performance improvement [1]

Group 1: Corporate Governance and Independent Directors - Independent directors have actively exercised their duties, ensuring objective and fair oversight, which has positively impacted the company's governance and the interests of minority shareholders [1][2] Group 2: Dividend Policy - The company plans to implement a cash dividend of CNY 0.26 per share for the year 2024, representing a distribution ratio of 49.39% of the net profit attributable to shareholders [2] - Future dividend frequency will depend on actual profitability, major investment needs, and regulatory changes [2] Group 3: Product Development and R&D - The company is the sole producer of Ruixiangsu capsules, focusing on diseases like viral pneumonia and type 2 diabetes complications, with two related patents obtained [2][3] - R&D expenses for 2024 are CNY 10.22 million, accounting for 3.99% of revenue, with a focus on iron supplement and circulatory disorder treatments [6][7] Group 4: Financial Performance - In 2024, the company reported a net profit of CNY 40.27 million, a decrease of 20.26% year-on-year, primarily due to reduced government subsidies [5] - Revenue for 2024 was CNY 256 million, reflecting a growth of 13.71% compared to the previous year [5] Group 5: Cash Flow and Investment Activities - Cash outflow from financing activities increased by 814.23% to CNY 120 million, mainly due to share buybacks aimed at stabilizing stock prices [3] - Net cash flow from investment activities decreased by 185.84%, attributed to reduced financial management scale and ongoing project investments [4] Group 6: Asset Management - Total assets as of December 31, 2024, were CNY 1.063 billion, a decrease of 0.43%, while net assets fell by 7.85% to CNY 906 million, largely due to share repurchase activities [5]

Group 1: Company Strategy and Development - The company adheres to a dual strategy of independent and collaborative research and development, enhancing its long-term development through strategic investments and internal resource integration [1] - The company aims to become a trusted and preferred provider of professional healthcare products, focusing on a unified operational system across R&D, marketing, and production [2] - The company plans to implement a four-pronged growth model encompassing OTC, prescription drugs, traditional Chinese medicine, and health products to support high-quality development [2] Group 2: Marketing and Sales Achievements - The company has established a comprehensive marketing system, covering over 3,000 chain pharmacies and approximately 240,000 cooperative chain stores, reaching over 90% of cities and 70% of districts nationwide [2] - The company’s online channel strategy includes partnerships with e-commerce platforms to enhance product accessibility and consumer engagement [2] Group 3: Financial Performance - In 2024, the pharmaceutical segment generated revenue of 915 million yuan, accounting for 82.96% of total revenue, with the "Kuaike" series contributing 612 million yuan, representing 55.49% of total revenue [3] - The company’s cold and flu medications account for approximately 56% of total revenue [4] Group 4: Product Development and Market Position - The "Kuaike" cold medicine has ranked first in the annual comprehensive statistics of non-prescription drugs in China for three consecutive years from 2021 to 2023 [3] - The company has successfully launched the "Kuaike Qing" oseltamivir capsules and has received re-listing permits for other products [1] Group 5: Future Plans and Challenges - The company is actively preparing for the flu season by optimizing production capacity and ensuring smooth supply channels [5] - The company is exploring opportunities in traditional Chinese medicine, developing high-quality products to enhance market share in this sector [5]